The CoMMpass Study℠
A groundbreaking study
In 2011, the MMRF launched the CoMMpass Study, the first of its kind in myeloma. A collaboration of world-class researchers in over 90 institutions — a “dream team” of cancer specialists — the CoMMpass Study is helping researchers gain access to each patient’s genetic analysis to help them learn how patients respond to therapies. The findings cannot be patented and all the data are placed on a public portal (the MMRF Researcher Gateway). The resulting data set will be the largest, most comprehensive catalog of multiple myeloma including the largest set of whole genome sequences. It will provide far more information than is possible from current cancer tissue banks that typically include one sample per patient.
Benefits for all
By participating in CoMMpass, patients will help accelerate the discovery and development of precision medicine for multiple myeloma — and be among the first to benefit from it as treatments become available.
Interested in participating in the CoMMpass Study? Contact the MMRF at 866-603-6628
Male or female 18 years or older, newly diagnosed, prior to start of treatment
Symptomatic multiple myeloma with measurable disease that includes at least one of the following:
- Serum M protein ≥1 g/dL – Urine M protein ≥ 200 mg/24 hr – Involved free light chain level >10 mg/dL and an abnormal serum free light chain ratio (1.65)
- Candidate for systemic therapy that includes an IMid® (eg, lenalidomide, pomalidomide, or thalidomide) and/or a proteasome inhibitor as part of the initial regimen
- No more than 30 days from baseline bone marrow evaluation to initiation of therapy
- Be able to read, understand, and sign the Informed Consent document
Patient is already receiving systemic therapy for multiple myeloma (a single dose of bisphosphonates and up to 100 mg total dose of dexamethasone or equivalent corticosteroids are permitted prior to registration on study)
Currently receiving systemic therapy for multiple myeloma. Please note that a single dose of bisphosphonates and up to 100 mg total dose of dexamethasone or equivalent corticosteroids are permitted prior to study registration
Prior (within the last 5 years) malignancy. Exceptions include basal or squamous cell carcinoma or in situ cancers of the cervix
Enrollment in a blinded clinical trial for the first-line treatment of multiple myeloma. Patients may be enrolled in subsequent clinical trials as long as continued access to data and tissue, as per this protocol, is not prohibited
More about the CoMMpass Study
The CoMMpass Study is at the center of the efforts of the MMRF to improve myeloma treatments and patient outcomes through personalized medicine. The information it collects will enable existing treatments to be tailored to specific patients based on their markers, and new targeted treatments to be identified and developed with research and industry collaborators.
The study follows newly diagnosed multiple myeloma patients, beginning before they’re treated, over a 10-year period to understand the molecular and genetic changes underpinning the disease as it evolves.